Presentations
- Erythema
- Hyperviscosity
- Incidental findings on blood test
- Thrombosis and bleeding
Conditions
- Chronic myeloid leukaemia
- Essential thrombocytosis (ET)
- Familial / Congenital erythrocytosis and thrombocytosis
- Hypereosinophilia syndromes
- Juvenile myelomonocytic leukaemia (JMML)
- Mastocytosis
- Myelofibrosis (MF)
- Polycythemia vera (PV)
- Transient abnormal myelopoiesis (TAM)
For each presentation and condition, Advanced Trainees will know how
to:
Synthesise
- recognise the clinical presentation
- identify relevant epidemiology, prevalence, pathophysiology, and clinical science
- take a comprehensive clinical history
- conduct an appropriate examination
- establish a differential diagnosis
- plan and arrange appropriate investigations
- consider the impact of illness and disease on patients and their quality of life when
developing a management plan
Manage
- provide evidence-based management
- prescribe therapies tailored to patients’ needs and conditions
- recognise potential complications of disease and its management, and initiate
preventative strategies
- involve multidisciplinary teams
Consider other factors
- identify individual and social factors and the impact of these on diagnosis and
management
Presentations
- Incidental finding on blood test
Conditions
- Atypical chronic myeloid leukaemia
- Myelodysplastic syndrome / Myeloproliferative neoplasm overlap syndromes
For each presentation and condition, Advanced Trainees will know how to:
Synthesise
- recognise the clinical presentation
- identify relevant epidemiology, prevalence, pathophysiology, and clinical science
- take a comprehensive clinical history
- conduct an appropriate examination
- establish a differential diagnosis
- plan and arrange appropriate investigations
- consider the impact of illness and disease on patients and their quality of life when
developing a management plan
Manage
- provide evidence-based management
- prescribe therapies tailored to patients’ needs and conditions
- recognise potential complications of disease and its management, and initiate
preventative strategies
- involve multidisciplinary teams
Consider other factors
- identify individual and social factors and the impact of these on diagnosis and
management
- Associated pathophysiology and morphology
- Genetic landscape of myeloproliferative neoplasms, such as:
- driving lesions
- risk stratification
- Mechanisms of myeloproliferative disease, including causes of symptoms
- Polycythaemia and thrombocytosis:
- acquired and secondary causes
- inherited causes
Investigations
- Clinical trial agents
- Clonal myeloproliferative neoplasms (MPNs):
- complications
- diagnostic criteria
- major differential diagnoses
- prognostic classification
- treatment, such as:
- pharmacological means
- radioisotope
- venesection
- venesection cut-off criteria for different polycythaemia groups
- Diagnostic criteria for juvenile myelomonocytic leukaemia (JMML) and myeloid proliferations
associated with Down syndrome
- Genomic testing for:
- congenital / inherited:
- polycythaemia
- thrombocytosis
- Watch and wait scenarios
Procedures
- Bone marrow biopsy
- Indications for stem cell transplant
- Non-surgical management of massive splenomegaly
- Common and serious complications of:
- ET
- MF, such as haemorrhage, leukaemia, and thrombosis, including:
- awareness of differences in incidence of these complications between the types of
myeloproliferative disorders (MPD)
- interaction of treatment on these complications
- PV
- Patient management throughout the course of illness
- Regular evaluation of treatment effectiveness, and at appropriate intervals
